Imaxio has signed an option for a license agreement with Merial, the animal health division of Sanofi, to develop an animal health vaccine based on Imaxio's immune-enhancing IMX313 technology.

Merial will conduct an internal review of the IMX313 technology for 12–18 months, and depending on the results, will sign a license agreement. Details of the vaccine candidate and the financial terms of the agreement have not yet been disclosed.


The aim of IMX313, Imaxio's proprietary technology for antigen re-engineering, is to significantly enhance the immune response and the efficiency of vaccines with which it is used. In response to the challenge of certain ineffiacious vaccine candidates, IMX313 is a high-potential solution, which would not only enable the dose to be reduced, but also the number of revaccinations needed, according to the company.